| Followers | 60 |
| Posts | 11408 |
| Boards Moderated | 0 |
| Alias Born | 01/31/2008 |
Friday, May 10, 2019 10:01:30 AM
Another question is on back of the Rett Syndrome trials, isn’t one of the differences also age, I thought I saw in the – on the clinical site – the FDA site that there was an age limit on the Rett trail on the U.S. have no age limit in Australia, but maybe you can just clarify both.
Christopher Missling
Yes. The age is actually in both very same, it’s 18 years and older. And as we continue the plan is according to our Rett Syndrome program to also add patients with younger age to the study as we continue.
Tom Bishop
So in other words, initially of the 30 patients in Australia, you start with 18 years and older and then within the 30, go below 18?
Christopher Missling
No. The plan is to start a study separately with younger patients. So 18 and older will stay the AVATAR study and other patients will be enrolled in a separate study, and that’s why we refer to the…
Tom Bishop
You got another two studies coming up. So yes, you got another Phase 2 study coming up.
Christopher Missling
That is the plan to move forward into younger patient population. That’s correct.
OK FOLKS, Dr. M just put out some more breadcrumbs for those who will see them. ZERO reason to start an under 18 Rett trial UNLESS they are getting good results in those over 18.
Christopher Missling
Yes. The age is actually in both very same, it’s 18 years and older. And as we continue the plan is according to our Rett Syndrome program to also add patients with younger age to the study as we continue.
Tom Bishop
So in other words, initially of the 30 patients in Australia, you start with 18 years and older and then within the 30, go below 18?
Christopher Missling
No. The plan is to start a study separately with younger patients. So 18 and older will stay the AVATAR study and other patients will be enrolled in a separate study, and that’s why we refer to the…
Tom Bishop
You got another two studies coming up. So yes, you got another Phase 2 study coming up.
Christopher Missling
That is the plan to move forward into younger patient population. That’s correct.
OK FOLKS, Dr. M just put out some more breadcrumbs for those who will see them. ZERO reason to start an under 18 Rett trial UNLESS they are getting good results in those over 18.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
